Document:

Exhibit 10.1

FERMAVIR PHARMACEUTICALS, INC.

AMENDMENT
AGREEMENT

This Amendment
Agreement dated as of March 19, 2007 (the “Amendment”) by and between                           
(the “Investor”) and FermaVir Pharmaceuticals, Inc., a Florida
corporation (the “Company”), amends certain provisions of Warrant No.             
expiring December 21, 2016, issued by the Company to the Investor (the “Prior
Warrant”).  Capitalized terms that are
used and not defined in this Amendment that are defined in the Prior Warrant
shall have the respective definitions set forth in the Prior Warrants.

WITNESSETH:

WHEREAS, the Prior Warrant includes an anti-dilution
provision which provides that in the event the Company shall offer, sell, grant any option to
purchase or offer, sell or grant any right to reprice its securities, or
otherwise dispose of or issue (or announce any offer, sale, grant or any option
to purchase or other disposition) any Common Stock or Common Stock Equivalents
entitling any Person to acquire shares of Common Stock, at an effective price
per share less than the then Exercise Price of the Prior Warrant (the “Base
Share Price”), then the Exercise Price shall be reduced and only reduced to
equal the Base Share Price and the number of Warrant Shares issuable thereunder
shall be increased such that the aggregate Exercise Price payable thereunder,
after taking into account the decrease in the Exercise Price, shall be equal to
the aggregate Exercise Price prior to such adjustment;

WHEREAS, the Investor and the Company have come to
an agreement as to the Investor  deleting
the anti-dilution provision from the Prior Warrant in exchange for adjusting
the Exercise Price of the Prior Warrant;

NOW,
THEREFORE, in consideration of and for the mutual promises and covenants contained
herein, and for other good and valuable consideration, the receipt of which is
hereby acknowledged, the parties agree as follow

SECTION 1.

1.1           Exercise Price.  The
exercise price of $1.00 set forth in the first paragraph of the Prior Warrant
is hereby amended to $0.525.

1.2           Other
Amendments.  Section 2.2 of the Prior Warrant is hereby deleted
in its entirety.

SECTION 2.

2.1           Effect on Prior Agreements.  Except
as amended hereby, the terms and provisions of the Prior Warrant shall remain
in full force and effect, and the Prior Warrant is in all respects ratified and
confirmed. On and after the date of this Amendment, each reference

in the Prior Note or Prior Warrant, as the case may be, to the “Warrant”,
“hereinaf­ter”, “herein”, “herein­after”, “hereunder”, “hereof”, or words of
like import shall mean and be a reference to the Prior Warrant as amended by
this Amendment.

SECTION 3.

3.1           Indemnity.  The
Investor agrees to indemnify and hold harmless the Company, its officers and
directors, employees and its affiliates and each other person, if any, who
controls any thereof, against any loss, liability, claim, damage and expense
whatsoever (including, but not limited to, any and all expenses whatsoever
reasonably incurred in investigating, preparing or defending against any
litigation commenced or threatened or any claim whatsoever) arising out of or
based upon any false representation or warranty or breach or failure by the
Investor to comply with any covenant or agreement made by the Investor herein
or in any other document furnished by the Investor to any of the foregoing in
connection with this transaction.

3.2           Modification.  Neither this Agreement nor any provisions
hereof shall be modified, discharged or terminated except by an instrument in
writing signed by the party against whom any waiver, change, discharge or
termination is sought.

3.3           Notices.  Any notice, demand or other communication
which any party hereto may be required, or may elect, to give to anyone
interested hereunder shall be sufficiently given if (a) deposited, postage
prepaid, in a United States mail letter box, registered or certified mail,
return receipt requested, addressed to such address as may be given herein, or
(b) delivered personally at such address.

3.4           Counterparts.  This Agreement may be executed through the
use of separate signature pages or in any number of counterparts, and each of
such counterparts shall, for all purposes, constitute one agreement binding on
all parties, notwithstanding that all parties are not signatories to the same
counterpart.

3.5           Binding Effect.  Except as otherwise provided herein, this
Agreement shall be binding upon and inure to the  benefit of the parties and their heirs,
executors, administrators, successors, legal representatives and assigns.  If the Investor is more than one person, the
obligation of the Investor shall be joint and several and the agreements,
representations, warranties and acknowledgments herein contained shall be
deemed to be made by and be binding upon each such person and his heirs,
executors, administrators and successors.

3.6           Entire Agreement.  This Agreement and the documents referenced
herein contain the entire agreement of the parties and there are no
representations, covenants or other agreements except as stated or referred to
herein and therein.

3.7           Assignability.  This Agreement is not transferable or
assignable by the Investor.

3.8           Applicable Law.  This Agreement shall be governed by and
construed in accordance with the laws of the State of New York, without giving effect
to conflicts of law principles.

 2
 

3.9           Pronouns.  The use herein of the masculine pronouns “him”
or “his” or similar terms shall be deemed to include the feminine and neuter
genders as well and the use herein of the singular pronoun shall be deemed to
include the plural as well.

IN
WITNESS WHEREOF, the Parties hereto have executed this Amendment as of the day
and year first written above.

	
  

  	
  FERMAVIR PHARMACEUTICALS, INC.

  
	
   

  	
   

  
	
   

  	
   

  
	
   

  	
  By:

  	
   

  
	
   

  	
   

  	
  Name:

  	
  Geoffrey W. Henson

  
	
   

  	
   

  	
  Title:

  	
  Chief Executive Officer

  
	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  
	
   

  	
  INVESTOR

  
	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  
	
   

  	
  Name:

  
					

 

 3Exhibit 10.2

FERMAVIR PHARMACEUTICALS, INC.

AMENDMENT
AGREEMENT

This Amendment
Agreement dated as of March 19, 2007 (the “Amendment”) by and between                  
(the “Investor”) and FermaVir Pharmaceuticals, Inc., a Florida
corporation (the “Company”), amends certain provisions of Warrant No.        
expiring January 10, 2017, issued by the Company to the Investor (the “Prior
Warrant”).  Capitalized terms that are
used and not defined in this Amendment that are defined in the Prior Warrant
shall have the respective definitions set forth in the Prior Warrants.

WITNESSETH:

WHEREAS, the Prior Warrant includes an anti-dilution
provision which provides that in the event the Company shall offer, sell, grant any option to
purchase or offer, sell or grant any right to reprice its securities, or
otherwise dispose of or issue (or announce any offer, sale, grant or any option
to purchase or other disposition) any Common Stock or Common Stock Equivalents
entitling any Person to acquire shares of Common Stock, at an effective price
per share less than the then Exercise Price of the Prior Warrant (the “Base
Share Price”), then the Exercise Price shall be reduced and only reduced to
equal the Base Share Price and the number of Warrant Shares issuable thereunder
shall be increased such that the aggregate Exercise Price payable thereunder,
after taking into account the decrease in the Exercise Price, shall be equal to
the aggregate Exercise Price prior to such adjustment;

WHEREAS, the Investor and the Company have come to
an agreement as to the Investor  deleting
the anti-dilution provision from the Prior Warrant in exchange for adjusting
the Exercise Price of the Prior Warrant;

NOW,
THEREFORE, in consideration of and for the mutual promises and covenants
contained herein, and for other good and valuable consideration, the receipt of
which is hereby acknowledged, the parties agree as follow

SECTION 1.

1.1           Exercise Price.  The
exercise price of $1.00 set forth in the first paragraph of the Prior Warrant
is hereby amended to $0.525.

1.2           Other
Amendments.  Section 2.2 of the Prior Warrant is hereby deleted
in its entirety.

SECTION 2.

2.1           Effect on Prior Agreements.  Except
as amended hereby, the terms and provisions of the Prior Warrant shall remain
in full force and effect, and the Prior Warrant is in all respects ratified and
confirmed. On and after the date of this Amendment, each reference in

the Prior Note or Prior Warrant, as the case may be, to the “Warrant”, “hereinaf­ter”,
“herein”, “herein­after”, “hereunder”, “hereof”, or words of like import shall
mean and be a reference to the Prior Warrant as amended by this Amendment.

SECTION 3.

3.1           Indemnity.  The
Investor agrees to indemnify and hold harmless the Company, its officers and
directors, employees and its affiliates and each other person, if any, who
controls any thereof, against any loss, liability, claim, damage and expense
whatsoever (including, but not limited to, any and all expenses whatsoever
reasonably incurred in investigating, preparing or defending against any
litigation commenced or threatened or any claim whatsoever) arising out of or
based upon any false representation or warranty or breach or failure by the
Investor to comply with any covenant or agreement made by the Investor herein
or in any other document furnished by the Investor to any of the foregoing in
connection with this transaction.

3.2           Modification.  Neither
this Agreement nor any provisions hereof shall be modified, discharged or
terminated except by an instrument in writing signed by the party against whom
any waiver, change, discharge or termination is sought.

3.3           Notices.  Any
notice, demand or other communication which any party hereto may be required,
or may elect, to give to anyone interested hereunder shall be sufficiently
given if (a) deposited, postage prepaid, in a United States mail letter box,
registered or certified mail, return receipt requested, addressed to such
address as may be given herein, or (b) delivered personally at such address.

3.4           Counterparts.  This
Agreement may be executed through the use of separate signature pages or in any
number of counterparts, and each of such counterparts shall, for all purposes,
constitute one agreement binding on all parties, notwithstanding that all
parties are not signatories to the same counterpart.

3.5           Binding Effect.  Except
as otherwise provided herein, this Agreement shall be binding upon and inure to
the  benefit of the parties and their
heirs, executors, administrators, successors, legal representatives and
assigns.  If the Investor is more than
one person, the obligation of the Investor shall be joint and several and the
agreements, representations, warranties and acknowledgments herein contained
shall be deemed to be made by and be binding upon each such person and his
heirs, executors, administrators and successors.

3.6           Entire Agreement.  This
Agreement and the documents referenced herein contain the entire agreement of
the parties and there are no representations, covenants or other agreements
except as stated or referred to herein and therein.

3.7           Assignability.  This
Agreement is not transferable or assignable by the Investor.

3.8           Applicable Law.  This Agreement shall be governed by and
construed in accordance with the laws of the State of New York, without giving
effect to conflicts of law principles.

3.9           Pronouns.  The use herein of the masculine pronouns “him”
or “his” or similar terms shall be deemed to include the feminine and neuter
genders as well and the use herein of the singular pronoun shall be deemed to
include the plural as well.

IN
WITNESS WHEREOF, the Parties hereto have executed this Amendment as of the day
and year first written above.

	
  

  	
  FERMAVIR PHARMACEUTICALS, INC.

  
	
   

  	
   

  
	
   

  	
   

  
	
   

  	
  By:

  	
   

  
	
   

  	
   

  	
  Name:

  	
  Geoffrey W. Henson

  
	
   

  	
   

  	
  Title:

  	
  Chief Executive Officer

  
	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  
	
   

  	
  INVESTOR

  
	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  
	
   

  	
  Name:

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00120-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00120-of-00352.parquet"}]]